PharmaResearch Co., Ltd. (KOSDAQ:214450)

South Korea flag South Korea · Delayed Price · Currency is KRW
288,000
+12,000 (4.35%)
Feb 21, 2025, 3:30 PM KST
214.75%
Market Cap 2.99T
Revenue (ttm) 317.00B
Net Income (ttm) 88.76B
Shares Out 10.39M
EPS (ttm) 8,057.05
PE Ratio 35.75
Forward PE 22.48
Dividend 950.00 (0.33%)
Ex-Dividend Date n/a
Volume 105,756
Average Volume 116,051
Open 279,500
Previous Close 276,000
Day's Range 278,000 - 289,500
52-Week Range 86,800 - 297,000
Beta 0.52
RSI 61.16
Earnings Date Feb 7, 2025

About PharmaResearch

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults thro... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1993
Employees 409
Stock Exchange KOSDAQ
Ticker Symbol 214450
Full Company Profile

Financial Performance

In 2023, PharmaResearch's revenue was 261.01 billion, an increase of 34.02% compared to the previous year's 194.76 billion. Earnings were 76.55 billion, an increase of 88.66%.

Financial Statements

News

There is no news available yet.